• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Firdapse (amifampridine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Firdapse (amifampridine)

  • Profile

Profile

Contact Information

Contact: Catalyst Pharmaceuticals
Website: www.firdapse.com

Currently Enrolling Trials

    Show More

    General Information

    Firdapse (amifampridine) is a potassium channel blocker. 

    Firdapse is specifically indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

    Fiedapse is supplied as a tablet for oral administration. The recommended starting dosage is 15 mg to 30 mg daily, taken orally in divided doses (3 to 4 times daily). The dosage can be increased by 5 mg daily every 3 or 4 days. The maximum recommended total daily dosage is 80 mg. The maximum single dose is 20 mg. If a dose is missed, patients should not take double or extra doses. 

    Mechanism of Action

    Firdapse (amifampridine) is a broad spectrum potassium channel blocker. The mechanism by which amifampridine exerts its therapeutic effect in LEMS patients has not been fully elucidated. 

    Side Effects

    Adverse effects associated with the use of Firdapse may include, but are not limited to, the following:

    • paresthesia
    • upper respiratory tract infection
    • abdominal pain
    • nausea
    • diarrhea
    • headache
    • elevated liver enzymes
    • back pain
    • hypertension
    • muscle spasms

    Clinical Trial Results

    The FDA approval of Firdapse was based on  two randomized, double-blind, placebo-controlled discontinuation studies. A total of 64 adults (age 21 to 88 years) with LEMS were enrolled (Study 1 and Study 2). Patients were required to be on an adequate and stable dosage (30 to 80 mg daily) of amifampridine phosphate prior to entering the randomized discontinuation phases of both studies. The two co-primary measures of efficacy in both studies were the change from baseline to the end of the discontinuation period in the Quantitative Myasthenia Gravis (QMG) score and in the Subject Global Impression (SGI) score. 

    Study 1: After an initial open-label run-in phase, 38 patients were randomized in a double-blind fashion to either continue treatment with Firdapse (n=16) or to a downward titration to placebo (n=22) over 7 days. Following the downward titration period, patients remained on blinded Firdapse or placebo for 7 more days. Efficacy was assessed at Day 14 of the double-blind period. Patients were allowed to use stable dosages of peripherally acting cholinesterase inhibitors or oral immunosuppressants. Twenty-six percent of patients randomized to Firdapse were receiving cholinesterase inhibitors, versus 36% in the placebo group, and 28% of patients randomized to Firdapse were receiving oral immunosuppressant therapies, versus 34% in the placebo group. During the double-blind period (from Baseline to Day 14), the QMG scores tended to worsen in both treatment groups, but there was significantly greater worsening in the placebo group than in the Firdapse group. Similarly, the SGI score tended to worsen in both treatment groups during the double-blind period, but there was significantly greater worsening in the placebo group than in the Firdapse group. These results indicate that in Study 1, patients randomized to placebo had a significantly greater worsening of muscle weakness and of global impression of the effects of the study treatment on their physical well-being, compared to patients who continued Firdapse in the double-blind period. 

    Study 2: Patients on stable treatment with Firdapse were randomized 1:1 in a double-blind fashion to either continue treatment with Firdapse (n=13) or change to placebo (n=13) for 4 days. Efficacy was assessed at the end of the 4-day double-blind discontinuation period. Patients were allowed to use stable doses of peripherally acting cholinesterase inhibitors or corticosteroids. From Baseline to Day 4, there was significantly greater worsening in the QMG score in the placebo group than in the Firdapse group, and also significantly greater worsening in the SGI score in the placebo group than in the Firdapse group. These results indicate that in Study 2, patients randomized to placebo had a significantly greater worsening of muscle weakness and of global impression of the effects of the study treatment on their physical well-being, compared to patients who continued Firdapse in the double-blind period.

    Approval Date: 2018-11-01
    Company Name: Catalyst Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 12Apr

      The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    • White House

      Trial Stakeholders Advise White House on Emergency Research Infrastructure

    • SurveywBlueBackground-360x240.png

      Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing